Literature DB >> 22356593

Cognitive deficits in a mouse model of pre-manifest Parkinson's disease.

Iddo Magen1, Sheila M Fleming, Chunni Zhu, Eddie C Garcia, Katherine M Cardiff, Diana Dinh, Krystal De La Rosa, Maria Sanchez, Eileen Ruth Torres, Eliezer Masliah, J David Jentsch, Marie-Françoise Chesselet.   

Abstract

Early cognitive deficits are increasingly recognized in patients with Parkinson's disease (PD), and represent an unmet need for the treatment of PD. These early deficits have been difficult to model in mice, and their mechanisms are poorly understood. α-Synuclein is linked to both familial and sporadic forms of PD, and is believed to accumulate in brains of patients with PD before cell loss. Mice expressing human wild-type α-synuclein under the Thy1 promoter (Thy1-aSyn mice) exhibit broad overexpression of α-synuclein throughout the brain and dynamic alterations in dopamine release several months before striatal dopamine loss. We now show that these mice exhibit deficits in cholinergic systems involved in cognition, and cognitive deficits in domains affected in early PD. Together with an increase in extracellular dopamine and a decrease in cortical acetylcholine at 4-6 months of age, Thy1-aSyn mice made fewer spontaneous alternations in the Y-maze and showed deficits in tests of novel object recognition (NOR), object-place recognition, and operant reversal learning, as compared with age-matched wild-type littermates. These data indicate that cognitive impairments that resemble early PD manifestations are reproduced by α-synuclein overexpression in a murine genetic model of PD. With high power to detect drug effects, these anomalies provide a novel platform for testing improved treatments for these pervasive cognitive deficits.
© 2012 The Authors. European Journal of Neuroscience © 2012 Federation of European Neuroscience Societies and Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22356593      PMCID: PMC3967873          DOI: 10.1111/j.1460-9568.2012.08012.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  63 in total

1.  Is quality of life in non-demented Parkinson's disease patients related to cognitive performance? A clinic-based cross-sectional study.

Authors:  N Klepac; V Trkulja; M Relja; T Babić
Journal:  Eur J Neurol       Date:  2008-02       Impact factor: 6.089

2.  Up-regulating BDNF with an ampakine rescues synaptic plasticity and memory in Huntington's disease knockin mice.

Authors:  Danielle A Simmons; Christopher S Rex; Linda Palmer; Vijay Pandyarajan; Vadim Fedulov; Christine M Gall; Gary Lynch
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-05       Impact factor: 11.205

3.  Enhanced frontal function in Parkinson's disease.

Authors:  R Cools; A Miyakawa; M Sheridan; M D'Esposito
Journal:  Brain       Date:  2009-12-07       Impact factor: 13.501

4.  Delayed response tasks in basal ganglia lesions in man: further evidence for a striato-frontal cooperation in behavioural adaptation.

Authors:  A Partiot; M Vérin; B Pillon; C Teixeira-Ferreira; Y Agid; B Dubois
Journal:  Neuropsychologia       Date:  1996-07       Impact factor: 3.139

5.  A new one-trial test for neurobiological studies of memory in rats. 1: Behavioral data.

Authors:  A Ennaceur; J Delacour
Journal:  Behav Brain Res       Date:  1988-11-01       Impact factor: 3.332

6.  Beneficial effects of galantamine on performance in the object recognition task in Swiss mice: deficits induced by scopolamine and by prolonging the retention interval.

Authors:  Natasja de Bruin; Bruno Pouzet
Journal:  Pharmacol Biochem Behav       Date:  2006-09-20       Impact factor: 3.533

Review 7.  Alpha-synuclein: between synaptic function and dysfunction.

Authors:  G Di Rosa; D Puzzo; A Sant'Angelo; F Trinchese; O Arancio
Journal:  Histol Histopathol       Date:  2003-10       Impact factor: 2.303

8.  Dementia and visual hallucinations associated with limbic pathology in Parkinson's disease.

Authors:  M E Kalaitzakis; L M Christian; L B Moran; M B Graeber; R K B Pearce; S M Gentleman
Journal:  Parkinsonism Relat Disord       Date:  2008-07-07       Impact factor: 4.891

9.  Probabilistic reversal learning is impaired in Parkinson's disease.

Authors:  D A Peterson; C Elliott; D D Song; S Makeig; T J Sejnowski; H Poizner
Journal:  Neuroscience       Date:  2009-07-21       Impact factor: 3.590

10.  Tonic dopamine modulates exploitation of reward learning.

Authors:  Jeff A Beeler; Nathaniel Daw; Cristianne R M Frazier; Xiaoxi Zhuang
Journal:  Front Behav Neurosci       Date:  2010-11-04       Impact factor: 3.558

View more
  34 in total

1.  Chronic nicotine improves cognitive and social impairment in mice overexpressing wild type α-synuclein.

Authors:  Sudhakar R Subramaniam; Iddo Magen; Nicholas Bove; Chunni Zhu; Vincent Lemesre; Garima Dutta; Chris Jean Elias; Henry A Lester; Marie-Francoise Chesselet
Journal:  Neurobiol Dis       Date:  2018-06-01       Impact factor: 5.996

2.  A Molecular Tweezer Ameliorates Motor Deficits in Mice Overexpressing α-Synuclein.

Authors:  Franziska Richter; Sudhakar R Subramaniam; Iddo Magen; Patrick Lee; Jane Hayes; Aida Attar; Chunni Zhu; Nicholas R Franich; Nicholas Bove; Krystal De La Rosa; Jacky Kwong; Frank-Gerrit Klärner; Thomas Schrader; Marie-Françoise Chesselet; Gal Bitan
Journal:  Neurotherapeutics       Date:  2017-10       Impact factor: 7.620

Review 3.  The neurobiological basis of cognitive impairment in Parkinson's disease.

Authors:  Glenda M Halliday; James B Leverenz; Jay S Schneider; Charles H Adler
Journal:  Mov Disord       Date:  2014-04-15       Impact factor: 10.338

4.  α-synuclein interacts with PrPC to induce cognitive impairment through mGluR5 and NMDAR2B.

Authors:  Diana G Ferreira; Mariana Temido-Ferreira; Hugo Vicente Miranda; Vânia L Batalha; Joana E Coelho; Éva M Szegö; Inês Marques-Morgado; Sandra H Vaz; Jeong Seop Rhee; Matthias Schmitz; Inga Zerr; Luísa V Lopes; Tiago F Outeiro
Journal:  Nat Neurosci       Date:  2017-09-25       Impact factor: 24.884

5.  Locomotor differences in mice expressing wild-type human α-synuclein.

Authors:  Genesys Giraldo; Mieu Brooks; Benoit I Giasson; Christopher Janus
Journal:  Neurobiol Aging       Date:  2018-02-06       Impact factor: 4.673

6.  Human LRRK2 G2019S mutation represses post-synaptic protein PSD95 and causes cognitive impairment in transgenic mice.

Authors:  Samuel O Adeosun; Xu Hou; Baoying Zheng; Heather L Melrose; Thomas Mosley; Jun Ming Wang
Journal:  Neurobiol Learn Mem       Date:  2017-05-06       Impact factor: 2.877

Review 7.  Non-motor features of Parkinson disease.

Authors:  Anthony H V Schapira; K Ray Chaudhuri; Peter Jenner
Journal:  Nat Rev Neurosci       Date:  2017-06-08       Impact factor: 34.870

8.  An unexpected improvement in spatial learning and memory ability in alpha-synuclein A53T transgenic mice.

Authors:  Qi Liu; YuYu Xu; WenPing Wan; ZeGang Ma
Journal:  J Neural Transm (Vienna)       Date:  2017-12-07       Impact factor: 3.575

9.  α-Synuclein interferes with the ESCRT-III complex contributing to the pathogenesis of Lewy body disease.

Authors:  Brian Spencer; Changyoun Kim; Tania Gonzalez; Alejandro Bisquertt; Christina Patrick; Edward Rockenstein; Anthony Adame; Seung-Jae Lee; Paula Desplats; Eliezer Masliah
Journal:  Hum Mol Genet       Date:  2016-01-05       Impact factor: 6.150

Review 10.  Basal Forebrain Cholinergic Circuits and Signaling in Cognition and Cognitive Decline.

Authors:  Elizabeth C Ballinger; Mala Ananth; David A Talmage; Lorna W Role
Journal:  Neuron       Date:  2016-09-21       Impact factor: 17.173

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.